Repurposing of Triazole Drugs to Combat Common Cancer Cases

Abstract

Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world. According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death. The discovery of new drugs is compulsory due to restrictions such as the side effects of currently used anti-cancer drugs, drug resistance developing over time, and so on. Unfortunately the development of novel drugs requires especially a long time and a huge amount of cost. At this point, the repurposing approach, which refers to the secondary use of various drugs that was approved by FDA for other purposes, has a vital importance. In this study, the anti-proliferative effects of ICZ and FCZ, which are actually antifungal drugs, on breast (MCF-7 and MDA-MB-231) and lung (A549) cancer cells were evaluated. Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

Keywords

• breast cancer
• fluconazole
• itraconazaole
• lung cancer
• repurposing
• meme kanseri
• flukonazol
• itrakonazol
• akciğer kanseri
• yeniden kullanım.